Meeting highlight View All

Reshaping CLL care: Acalabrutinib-based regimens at the forefront of CLL management

09 May 2024

Dr. Jeff Sharman

Willamette Valley Cancer Institute and Research Center,
Eugene, United States

infographics View All

From bridging to maintenance: A case of gilteritinib in RR FLT3 AML patients undergoing HSCT

09 May 2024